INTRODUCTION
============

Inherited peripheral neuropathies (IPNs) are a group of disorders comprising clinically heterogeneous diseases. These include hereditary motor and sensory neuropathy (usually called Charcot-Marie-Tooth disease: CMT), distal hereditary motor neuropathy (dHMN), hereditary sensory autonomous neuropathy (HSAN), hereditary neuropathy with a liability to pressure palsy (HNPP), and congenital hypomyelinating neuropathy (CHN) ([@b12-molce-39-5-382]; [@b18-molce-39-5-382]). IPNs are characterized by progressive distal motor weakness, sensory loss, and areflexia in the upper and lower limbs. Genetically, IPNs are very heterogeneous and over 70 related genes have been filed ([@b20-molce-39-5-382]; [@b22-molce-39-5-382]). They have shown the loose genotype-phenotype correlation and phenotypic overlapping between the disease types ([@b9-molce-39-5-382]; [@b15-molce-39-5-382]). Mutations in a specific gene frequently cause different types of IPNs, whereas similar phenotypes are usually caused by different genetic defects. As an example, mutations in the *MPZ* gene (MIM 159440) are known to cause several IPN types including dominant CMT1B (MIM 118200), CMT2I (MIM 607677), CMT2J (MIM 607736), DSS (MIM 145900), DI-CMTD (MIM 607791), and recessive CHN (CMT4E, MIM 605253). This clinical and genetic heterogeneity makes their exact diagnosis difficult.

Although the genetic diagnosis of IPNs has been conventionally dependent on the direct sequencing of major causative genes, it has low isolation efficiency in spite of the laborious procedure. The recent advent of whole exome sequencing (WES) based on the next-generation sequencing (NGS) technique has broadened and accelerated the analysis of various disorders at the level of genome especially in heterogeneous disorder groups such as IPNs ([@b4-molce-39-5-382]; [@b7-molce-39-5-382]; [@b9-molce-39-5-382])., WES is particularly efficient for identifying rare genetic causes from wide-ranging causative genes. Application of WES to CMT has several additional benefits. WES is cost- and time-effective compared to previous methods or procedures. In addition, advances in detection algorithms for single nucleotide variation (SNV), has increased their accuracy. From the first application in 2011 ([@b13-molce-39-5-382]), NGS has been applied in more than hundreds studies to isolate underlying causes of IPN. More recently, targeted multi-gene panel sequencing has been applied as an alternative method for genetic testing of several neuropathic disorders ([@b1-molce-39-5-382]; [@b26-molce-39-5-382]). Multi-gene panel testing is particularly effective for the diagnosis of neurodegenerative disorders with large clinical and pathogenic spectra.

Here, we designed and validated a new targeted gene panel for one step, simultaneous genetic diagnosis of IPNs by detection of 17p12 duplication and SNVs in subject of 78 Korean IPN families.

MATERIALS AND METHODS
=====================

Subjects
--------

This study enrolled a total of 78 Korean IPN families (89 affected and 46 unaffected individuals) with variable subtypes, such as CMT1, CMT2, intermediate CMT (IntCMT), dHMN, and HSAN ([Table 1](#t1-molce-39-5-382){ref-type="table"}). Of the IPN families, 15 CMT1A (MIM 118220) families who were previously diagnosed to have 17p12 (*PMP22*) duplication were included. In addition, 300 healthy Korean controls were included in this study. All participants provided written informed consents according to the protocol approved by the Institutional Review Board for Sungkyunkwan University, Samsung Medical Center (\#SMC2013-10-066).

Clinical assessments
--------------------

Clinical information included motor and sensory impairments, deep tendon reflexes, and muscle atrophy. Age at onset was determined by asking patients for their ages, when symptoms (i.e., distal muscle weakness, foot deformity, or sensory change) first appeared. Physical disability was measured by the functional disability scale (FDS) and the CMT neuropathy score (CMTNS). Nerve conduction studies including motor and sensory conduction velocities were measured on the median, ulnar, peroneal, tibial, and sural nerves.

DNA purification and prescreening of 17p12 duplication
------------------------------------------------------

Genomic DNA was purified from peripheral blood using a QIAamp blood DNA purification kit (Qiagen, Germany). All patient family samples were prescreened for the 17p12 (*PMP22*) duplication, which is the most frequent genetic cause of demyelinating CMT, using a hexaplex microsatellite PCR ([@b3-molce-39-5-382]).

Design and preparation of gene panel
------------------------------------

A total of 73 target genes were selected by extensive search of literatures and databases ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). A total of 1669 regions were read by 6298 probes with coverage of 99.5%. The probe design was performed according to Suredesign website (<https://earray.chem.agilent.com/suredesign>), and then DNA samples were prepared using the SureSelect DNA Sample Preparation System (Agilent Technologies, USA). Quality control and quantification of the prepared libraries were performed by Macrogen, Inc. (Korea).

Sequencing and identification of causative mutations
----------------------------------------------------

Sequencing was performed using a HiSeq 2000 Genome Analyzer (Illumina, USA) and the UCSC assembly hg19 (GRCh37) was used as the reference sequence(<http://genome.ucsc.edu>). Functionally significant variants (missense, nonsense, exonic insertion/deletion (indel), and splicing site variants) were selected, and then novel or uncommon variants (minor allele frequency ≤ 0.01) were further selected by searching the globally available human genome variant databases, such as dbSNP144 databases (<http://www.ncbi.nlm.nih.gov>), the 1000 Genomes Project (1000G) (<http://www.1000genomes.org/>), Exome Variant Project (ESP) (<http://evs.gs.washington.edu/EVS/>), and the Exome Aggregation Consortium (ExAC) (<http://exac.broadinstitute.org/>). The Sanger's sequencing method was applied to confirm candidate variants in the extended family members using a genetic analyzer ABI3130XL (Life Technologies, USA). For the finally selected pathogenic or likely pathogenic variants, the genomic evolutionary rate profiling (GERP) scores were determined by the GERP++ program (<http://mendel.stanford.edu/SidowLab/downloads/gerp/index.html>). *In silico* analyses of the mutant proteins were performed using the prediction algorithms of SIFT (<http://sift.jcvi.org>), MUpro (<http://www.ics.uci.edu/~baldig/mutation>), and PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>).

RESULTS
=======

General properties of the targeted-gene diagnostic panel
--------------------------------------------------------

The gene panel included 73 IPN-relevant genes and one control gene with a target size of 276 kb ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). We performed genetic tests for 74 genetically un-diagnosed CMT patients who had been excluded 17p12 (*PMP22*) duplication ([Table 1](#t1-molce-39-5-382){ref-type="table"}). Mean read depth was 194.8X, and target coverage with read depth of ≥10X was 98.9% (Supplementary Table S2). Total numbers of SNVs (including SNPs and indels) were from 325 (FC290-1) to 434 (FC678-4) with average of 377 from 73 target genes (except for *TEKT3*). Of them, functionally significant SNVs were observed from 25 (FC182-1) to 45 (FC693-1). These significant SNVs were further selected by the filtering steps of co-segregation analysis within each family, healthy control experiment (n = 300), and a screen of global human genome variant databases (dbSNP144, 1000G, ESP, and ExAC).

Identification of causative mutations
-------------------------------------

From subsequent filtering and capillary sequencing of candidate variants, we were able to isolate 15 pathogenic or likely-pathogenic mutations in 17 families: 6 *GJB1* (MIM 304040) mutations in 9 X-linked CMTX1 (MIM 302800) families; 2 *MPZ* (MIM 159440) mutations in CMT2I (MIM 607677); a pair of compound heterozygote mutations of *SH3TC2* (MIM 608206) in a CMT4C (MIM 601596) family; and one mutation each in *PMP22* (MIM 601097) in CMT1E (MIM 118300), *MARS* (MIM 156560) in CMT2U (MIM 616280), *MFN2* (MIM 608507) in CMT2A (MIM 609260), *SPTLC2* (MIM 605713) in HSAN1C (MIM 613640), and *DCTN1* (MIM 601143) in dHMN7B (MIM 607641) ([Table 2](#t2-molce-39-5-382){ref-type="table"}). Most families showed dominant inheritance of the neuropathy phenotype except a CMT4C family (FC703) with compound heterozygote mutations in *SH3TC2*.

Eight mutations had not yet been reported as pathogenic mutations. The novel mutations were well co-segregated with affected individual(s) in each family ([Fig. 1](#f1-molce-39-5-382){ref-type="fig"}). The mutations were confirmed by the Sanger's sequencing method ([Fig. 2A](#f2-molce-39-5-382){ref-type="fig"}) and were not found in 300 control samples. In addition, they were not reported or very rarely reported in several global human genome databases, such as dbSNP144, 1000G, ESP, and ExAC ([Table 3](#t3-molce-39-5-382){ref-type="table"}). The mutation sites were located at the highly conserved regions among the vertebrate species ([Fig. 2B](#f2-molce-39-5-382){ref-type="fig"}). The GERP scores were high at most mutation sites (3.36 to 5.76) and *in silico* analyses also predicted most of them to be pathogenic. Therefore, we considered these mutations to be the genetic cause.

Interestingly, c.283G \> A (p.V95M) mutation in *GJB1* was identified in three independent families with a wide range of onset ages (8--48), suggesting a loose genotype-phenotype correlation and mutational hot spot. Mutations in *MPZ* are implicated into many types of IPN with the most frequent type of demyelinating CMT1B; however, in the present study, both cases with *MPZ* mutations exhibited less frequent axonal defect of the CMT2I. The p.R280H mutation of *MFN2* has shown occasional incomplete penetrance ([@b5-molce-39-5-382]); however, the present case was completely penetrant within the family (FC527). Two *de novo* mutations were suggested in FC541 family with p.L16R in *PMP22* and FC141 family with p.Y88H in *MPZ*. No same mutation was found in the unaffected parents of FC541 family; whereas *de novo* event were predicted by the history taking in the FC141 family.

Detection of duplication of chromosome 17p12 region
---------------------------------------------------

We calculated the effectiveness of the gene panel in detecting the duplication of 1.4 Mb in the 17p12 region. We applied 15 samples of CMT1A duplication patients who were previously confirmed by the microsatellite hexaplex PCR and real-time PCR methods. Read depths of *PMP22* and *TEKT3* genes, which are located in the duplication region (17p12), were compared with the average read depth of total targets in each targeted sequencing data. Compared with five non-duplicated healthy controls, CMT1A patients showed significantly higher read depths in both genes: 1.496 ± 0.098 for *PMP22* and 1.472 ± 0.119 for *TEKT3*, with a mean of 1.484 ± 0.105 for both genes ([Table 4](#t4-molce-39-5-382){ref-type="table"}). Because these values are approaching the hypothetical value of 1.5-fold, the gene panel seems to be sufficient to detect the 1.4 Mb duplication of CMT1A patients.

Clinical features of IPN patients
---------------------------------

The brief clinical manifestations of affected individuals are shown in [Table 2](#t2-molce-39-5-382){ref-type="table"}. The onset ages ranged from 1 to 49 years for the proband individuals, where the ages were earlier than 5 years in patients with *PMP22, SH3TC2* and *MARS* mutations. High FDS (score 6 or 7) was found only in the FC541 with *PMP22* mutation, the other patients showed mild or moderate symptoms with low FDSs (score ≤ 3). This targeted gene panel study, in particular, found several very rare mutations in *SPTLC2*, *DCTN1,* and *MARS*.

A novel p.R145S mutation in *SPTLC2* was identified in a HSAN1C female patient (FC395) with onset of second decade. She revealed progressive sensory impairment resulting in ulcerations and amputations. Sensory loss occurred in a glove and stocking distribution, and pinprick perception was affected to a greater extent than vibration. She had painful tingling in both hands. Sensory complications including ulcers and accidental burns occurred, and severe wasting and weakness were present. SPTLC2 is a subunit of serine palmitoyltransferase (SPT) enzyme, and a crucial element in the *de novo* biosynthesis of sphingolipids. To date, only several HSAN1C families have been described ([@b8-molce-39-5-382]; [@b21-molce-39-5-382]), and this was the first reported Asian case.

A 12-year-old boy (FC180) showed a novel p.E340G mutation in *DCTN1*, which is known to cause dHMN7B. He complained of gait difficulty and hand muscle weakness at the age of 10 years. He had respiratory distress while talking, and distal dominant weakness in upper and lower limbs. In his hands, there was atrophy and weakness of the first dorsal interosseous and thenar muscles, but his hypothenar muscle bulk and strength was relatively preserved. Sensation was intact to all modalities. The findings of nerve conduction study and electromyogram were consistent with pure motor neuropathy. The *DCTN1* encodes the largest subunit of dynactin 1, which plays an important role in retrograde axonal transport of vesicles and organelles. Since the first dHMN7B patient were described in 2003 ([@b19-molce-39-5-382]), there has not been another case reported.

This study also found a CMT2U family (FC495) with p.P800T mutation in *MARS*, which was previously reported in a late-onset (50--60 years of age) CMT2 family ([@b11-molce-39-5-382]). However, the present family with the same *MARS* mutation showed relatively early onset development (ages of 5 and 16 years) compared to previous case. This suggests variability of age at onset in CMT2U. Until now, only two *MARS* mutations have been reported to be associated with axonal CMT ([@b10-molce-39-5-382]; [@b11-molce-39-5-382]).

DISCUSSION
==========

We developed a new IPN diagnostic tool that enables one-step detection of both 17p12 duplication and SNVs in target genes. Traditionally, genetic diagnosis of IPN adopted a tiered detection system, with considerable time and cost, involves determination of phenotype based on motor nerve conduction velocity, detection of chromosome 17p12 region duplication; then capillary sequencing for major genes with high frequency ([@b14-molce-39-5-382]; [@b23-molce-39-5-382]). In accordance with the technological ripeness in NGS, the simplest diagnostic algorithm was also proposed, where exome sequencing was included right after screening of *PMP22* duplication for CMT1, and *MFN2* mutations for CMT2 ([@b6-molce-39-5-382]). In spite of the laborious procedures in each step, however, the rate of successful isolation has been less than 60%.

Compared to previous processes, the newly developed diagnostic system strikingly reduced the time and cost with better detection efficiency. We applied the new system to 74 non-CMT1A patients (63 families) and isolated the causative mutations from 25 patients (17 families). Considering that CMT1A families were ruled out in this study, the gene panel exhibited high diagnostic yield. Technically, the major difference between WES and the targeted gene panel is the number of genes, which determines the cost and time. In addition, the reduced number of target sequences enhances read-depth and coverage, the major concerns of WES. Lower read-depth and coverage cause miscalling of false-positives and true-negatives, respectively, of potent SNPs. Using the gene panel, we could increase the read-depth to more than 10 times higher and the coverage to almost 100%. Therefore, application of the new targeted gene panel for IPNs can significantly enhance the effectiveness of genetic diagnosis.

To create a one-step diagnosis system, we also included a detection strategy for the copy number variation (CNV) of the chromosome 17p12 region. The current method, a short nucleotide read-based NGS, has a disadvantage in the detection of CNV for a long ranged targets. Previously, we demonstrated that detection of *PMP22* duplication is simply achieved by the application of six markers with 99.9% of efficiency ([@b3-molce-39-5-382]). In the new gene panel system, we designed a CNV detection strategy by comparing the read-depth of marker sequences. Because the mean read-depth of the duplication region was close to 1.5 fold higher than other regions and controls, the new strategy was sufficiently effective for CNV detection of CMT1A. These data also imply that the new gene panel can be applied to detection of HNPP, a disease caused by deletion of the same region.

In addition, the application of this gene panel could be used for association study. Recently, a SNP of *LITAF* (relating with CMT1C), was reported to be associated with the onset age of CMT1A and HNPP ([@b25-molce-39-5-382]). Since all IPN causative genes are simultaneously sequenced at the same time, future accumulation of genetic diagnosis data might facilitate the finding of new phenotype-modulating SNPs.

Collectively, we prepared a new one-step diagnosis tool that works without any prescreening, of which applicability was validated. Because the list of genetic causes of IPNs is still growing, continuous updating of the list in the gene panel could facilitate the exact genetic diagnosis of various peripheral neuropathies.
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Note: Supplementary information is available on the Molecules and Cells website ([www.molcells.org](www.molcells.org)).

![Pedigrees of inherited peripheral neuropathy families with novel pathogenic or likely pathogenic mutations. Arrows indicate the proband in each family. Open and black symbols represent the unaffected and affected individuals, respectively, whereas grey symbols indicate individuals with no clinical information available. Genotypes of the mutations are indicated at the bottom of all examined individuals (mutant allele: bold underlined): (A) FC541 family with c.47T \> C in *PMP22*, (B) FC703 with c.929G \> A and c.3272G \> T in *SH3TC2*, (C) FC156 with c.154T \> G in *MPZ*, (D) FC141 with c.262T \> C in *MPZ*, (E) FC180 with c.1019A \> G in *DCTN1*, (F) FC725 with c.286G \> C in *GJB1*, and (G) FC459 with c.435G \> T in *SPTLC2*.](molce-39-5-382f1){#f1-molce-39-5-382}

![Sequencing chromatograms and conservation analysis of novel causative mutations. (A) Confirmation of the causative mutations using the Sanger's sequencing method. (B) Alignment of the amino acid sequences for the mutation sites and around regions in several vertebrate species: *Homo sapiens*, *Bos taurus*, *Rattus norvegicus*, *Mus musculus*, *Gallus gallus*, *Xenopus laevis*, and *Danio rerio*.](molce-39-5-382f2){#f2-molce-39-5-382}

###### 

Inherited peripheral neuropathy families involved in target sequencing

  Type[^a^](#tfn1-molce-39-5-382){ref-type="table-fn"}   Family number   Subject number   Genetically diagnosed family         
  ------------------------------------------------------ --------------- ---------------- ------------------------------ ----- ----
  CMT1                                                   16              17               6                              23    1
  CMT2                                                   30              32               23                             55    4
  CMT4                                                   1               1                3                              4     1
  CMTX                                                   12              19               8                              27    9
  dHMN                                                   2               2                1                              3     1
  HSAN                                                   2               3                0                              3     1
  CMT1A                                                  15              15               5                              20    \-
                                                                                                                               
  Total                                                  78              89               46                             135   17

CMT1, Charcot-Marie-Tooth disease type 1 with autosomal dominant demyelination; CMT2, CMT type 2 with axonal defect; CMT4, CMT type 4 with autosomal dominant demyelination; dHMN, distal hereditary motor neuropathy; HSAN, hereditary sensory autonomous neuropathy; CMT1A, CMT type 1A with 17p12 duplication.

###### 

Summary of pathogenic or likely pathogenic mutations from the gene panel sequencing

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type     Gene       Mutation                   Family                     Inheriting mode   Onset (yrs)   Severity[^b^](#tfn4-molce-39-5-382){ref-type="table-fn"}   References       
  -------- ---------- -------------------------- -------------------------- ----------------- ------------- ---------------------------------------------------------- ------------ --- -----------------------
  CMT1E    *PMP22*    c.47T \> C                 p.L16R^\*^                 FC541             AD\           1                                                          24           6   This study
                                                                                              *de novo*                                                                                 

  CMT4C    *SH3TC2*   c.929G \> A+c.3272G \> T   p.G310E^\*^+p.G1091V^\*^   FC703             AR            5                                                          15           3   This study

  CMT2A    *MFN2*     c.839G \> A                p.R280H                    FC527             AD            45                                                         10           3   [@b6-molce-39-5-382]

  CMT2I    *MPZ*      c.154T \> G                p.F52V^\*^                 FC156             AD            25                                                         16           3   This study

                      c.262T \> C                p.Y88H^\*^                 FC141             AD\           20                                                         17           3   This study
                                                                                              *de novo*                                                                                 

  CMT2U    *MARS*     c.2398C \> A               p.P800T                    FC495             AD            5                                                          5            1   [@b11-molce-39-5-382]

  CMTX1    *GJB1*     c.20A \> G                 p.Y7C                      FC718             XD            15                                                         12           2   [@b24-molce-39-5-382]

                      c.43C \> T                 p.R15W                     FC751             XD            49                                                         5            1   [@b16-molce-39-5-382]

                      c.283G \> A                p.V95M                     FC565             XD            48                                                         9            2   [@b2-molce-39-5-382]

                                                                            FC687             XD            8                                                          4            1   

                                                                            FC698             XD            40                                                         11           2   

                      c.286G \> C                p.A96P^\*^                 FC725             XD            11                                                         12           2   This study

                      c.490C \> T                p.R164W                    FC714             XD            30                                                         15           4   [@b17-molce-39-5-382]

                      c.491G \> A                p.R164Q                    FC254             XD            15                                                         11           2   [@b2-molce-39-5-382]

                                                                            FC722             XD            8                                                          20           3   

  HSAN1C   *SPTLC2*   c.435G \> T                p.R145S^\*^                FC459             AD            17                                                         15           3   This study

  dHMN7B   *DCTN1*    c.1019A \> G               p.E340G^\*^                FC180             AD            10                                                         12           3   This study
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AA, amino acid; AD, autosomal dominant; AR, autosomal recessive; CMTNS, Charcot-Marie-Tooth disease neuropathy score; FDS, functional disability scale; Nt, nucleotide; XD, X-linked dominant

Mutations with ^\*^: likely pathogenic

CMTNS: mild: ≤10, moderate: 11--20, and severe: ≥21; FDS: 0: normal, 1: normal but with cramps and fatigability, 2: an inability to run, 3: walking difficulty but still possible unaided, 4: walking with a cane, 5: walking with crutches, 6: walking with a walker, and 7: wheelchair bound, and 8, bedridden.

###### 

Characterization of novel pathogenic mutations

  Genes      Mutations     Human genome DB search[^a^](#tfn5-molce-39-5-382){ref-type="table-fn"}   GERP[^b^](#tfn6-molce-39-5-382){ref-type="table-fn"}   *In silico* analysis[^c^](#tfn7-molce-39-5-382){ref-type="table-fn"}                                                                                                                                                                                         
  ---------- ------------- ------------------------------------------------------------------------ ------------------------------------------------------ ---------------------------------------------------------------------- ---------- ------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------
  *PMP22*    p.L16R        \-                                                                       \-                                                     \-                                                                     \-         3.36                                                    0.00[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}    0.760[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}    −0.375[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}
  *SH3TC2*   p.G310E       rs763949764                                                              \-                                                     \-                                                                     \< 0.001   4.88                                                    0.00[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}    1.000[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}    −0.288[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}
  p.G1091V   rs761592620   \-                                                                       \-                                                     \< 0.001                                                               5.76       0.00[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}   1.000[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}   −1.000[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}   
  *MPZ*      p.F52V        \-                                                                       \-                                                     \-                                                                     \-         5.29                                                    0.00[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}    1.000[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}    −0.542[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}
  p.Y88H     \-            \-                                                                       \-                                                     \-                                                                     4.70       0.00[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}   0.997[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}   0.034                                                     
  *GJB1*     p.A96P        \-                                                                       \-                                                     \-                                                                     \-         4.67                                                    0.00[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}    1.000[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}    −0.694[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}
  *SPTLC2*   p.R145S       rs749262868                                                              \-                                                     \-                                                                     \<0.001    5.23                                                    0.01[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}    0.004                                                     −1.000[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}
  *DCTN1*    p.E340G       \-                                                                       \-                                                     \-                                                                     \-         4.32                                                    0.00[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}    1.000[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}    −0.917[^\*^](#tfn8-molce-39-5-382){ref-type="table-fn"}

Human genome databases: the GenBank registration No (dbSNP144) or variant allele frequencies at the 1000 Genome Project (1000G: Nov, 2014), the Exome Sequencing Project (ESP: Nov, 2014), and the Exome Aggregation Consortium (ExAC: ver. 0.3)

GERP: genomic evolutionary rate profiling score

*In silico* analyses using the SIFT (<http://sift.jcvi.org>), PolyPhen2 (PP2: <http://genetics.bwh.harvard.edu/pph2/>), and MUpro (<http://www.ics.uci.edu/~baldig/mutation>) programs

indicates prediction of pathogenicity.

###### 

Detection of copy number variation for chromosome 17p12 region

  Samples                   Read depth ratios[^a^](#tfn9-molce-39-5-382){ref-type="table-fn"}   Mean            
  ------------------------- ------------------------------------------------------------------- --------------- ---------------
  Controls (n = 5)          1.000 ± 0.060                                                       1.000 ± 0.082   1.000 ± 0.069
    FC425-1                 1.081                                                               1.046           1.064 ± 0.025
    FC453-1                 0.989                                                               0.962           0.976 ± 0.019
    FC565-1                 1.064                                                               1.079           1.072 ± 0.011
    FC703-1                 0.872                                                               0.935           0.904 ± 0.045
    FC707-1                 0.993                                                               0.977           0.985 ± 0.011
  CMT1A patients (n = 15)   1.496 ± 0.098                                                       1.472 ± 0.119   1.484 ± 0.105
    FC045-12                1.435                                                               1.440           1.438 ± 0.003
    FC144-1                 1.468                                                               1.439           1.453 ± 0.020
    FC168-1                 1.615                                                               1.630           1.623 ± 0.010
    FC175-1                 1.468                                                               1.459           1.463 ± 0.006
    FC179-1                 1.518                                                               1.568           1.543 ± 0.035
    FC214-3                 1.678                                                               1.705           1.692 ± 0.018
    FC215-2                 1.395                                                               1.381           1.388 ± 0.009
    FC226-1                 1.548                                                               1.528           1.538 ± 0.014
    FC287-1                 1.578                                                               1.418           1.498 ± 0.113
    FC339-1                 1.623                                                               1.649           1.636 ± 0.018
    FC498-1                 1.328                                                               1.303           1.315 ± 0.017
    FC511-1                 1.414                                                               1.348           1.381 ± 0.047
    FC512-1                 1.414                                                               1.422           1.418 ± 0.005
    FC561-1                 1.504                                                               1.436           1.470 ± 0.048
    FC589-1                 1.449                                                               1.356           1.402 ± 0.065

Read depth ratios were determined by comparison with the mean read depth of control samples (n = 5) in each *PMP22* and *TEKT3* gene (control was indicated by 1.000).
